Tags

Type your tag names separated by a space and hit enter

Impact of early or delayed cyclosporine on delayed graft function in renal transplant recipients: a randomized, multicenter study.
Am J Transplant 2006; 6(5 Pt 1):1042-8AJ

Abstract

The benefit of delayed cyclosporine in reducing risk of delayed graft function (DGF) is not clearly established. This study compared early vs. delayed cyclosporine microemulsion (CsA-ME) inde novorenal transplant patients. Patients were randomized to early (day 0, n=97) or delayed (day 6, n=100) CsA-ME at an initial dose of 8 mg/kg/day with dose adjusted according to C2 level. All patients received enteric-coated mycophenolate sodium (EC-MPS), steroids and an anti-interleukin-2 receptor antibody. In both groups, 33% of patients were at high risk of DGF; 26 patients (26.8%) in the early CsA-ME group and 23 patients (23.0%) in the delayed CsA-ME group experienced DGF (n.s.). Renal function at 3 months was comparable (creatinine clearance 51.1 mL/min with early CsA-ME and 53.8 mL/min with delayed CsA-ME), and remained similar to 12 months. Treatment failure, defined as biopsy-proven acute rejection, graft loss or death, did not differ significantly at 12 months (23.7% with early CsA-ME vs. 29.0% with delayed CsA-ME). Biopsy-proven acute rejection occurred in 15.5% of early CsA-ME and 26.5% of delayed CsA-ME patients (n.s.). Both regimens were well tolerated. These data suggest that early or delayed introduction of CsA-ME results in similar renal function in renal transplant patients regardless of DGF risk level.

Authors+Show Affiliations

Department of Nephrology-Transplantation, Hôpital Rangueil, Toulouse, France. kamar.n@chu-toulouse.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16611342

Citation

Kamar, N, et al. "Impact of Early or Delayed Cyclosporine On Delayed Graft Function in Renal Transplant Recipients: a Randomized, Multicenter Study." American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, vol. 6, no. 5 Pt 1, 2006, pp. 1042-8.
Kamar N, Garrigue V, Karras A, et al. Impact of early or delayed cyclosporine on delayed graft function in renal transplant recipients: a randomized, multicenter study. Am J Transplant. 2006;6(5 Pt 1):1042-8.
Kamar, N., Garrigue, V., Karras, A., Mourad, G., Lefrançois, N., Charpentier, B., ... Rostaing, L. (2006). Impact of early or delayed cyclosporine on delayed graft function in renal transplant recipients: a randomized, multicenter study. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 6(5 Pt 1), pp. 1042-8.
Kamar N, et al. Impact of Early or Delayed Cyclosporine On Delayed Graft Function in Renal Transplant Recipients: a Randomized, Multicenter Study. Am J Transplant. 2006;6(5 Pt 1):1042-8. PubMed PMID: 16611342.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Impact of early or delayed cyclosporine on delayed graft function in renal transplant recipients: a randomized, multicenter study. AU - Kamar,N, AU - Garrigue,V, AU - Karras,A, AU - Mourad,G, AU - Lefrançois,N, AU - Charpentier,B, AU - Legendre,C, AU - Rostaing,L, PY - 2006/4/14/pubmed PY - 2006/6/24/medline PY - 2006/4/14/entrez SP - 1042 EP - 8 JF - American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons JO - Am. J. Transplant. VL - 6 IS - 5 Pt 1 N2 - The benefit of delayed cyclosporine in reducing risk of delayed graft function (DGF) is not clearly established. This study compared early vs. delayed cyclosporine microemulsion (CsA-ME) inde novorenal transplant patients. Patients were randomized to early (day 0, n=97) or delayed (day 6, n=100) CsA-ME at an initial dose of 8 mg/kg/day with dose adjusted according to C2 level. All patients received enteric-coated mycophenolate sodium (EC-MPS), steroids and an anti-interleukin-2 receptor antibody. In both groups, 33% of patients were at high risk of DGF; 26 patients (26.8%) in the early CsA-ME group and 23 patients (23.0%) in the delayed CsA-ME group experienced DGF (n.s.). Renal function at 3 months was comparable (creatinine clearance 51.1 mL/min with early CsA-ME and 53.8 mL/min with delayed CsA-ME), and remained similar to 12 months. Treatment failure, defined as biopsy-proven acute rejection, graft loss or death, did not differ significantly at 12 months (23.7% with early CsA-ME vs. 29.0% with delayed CsA-ME). Biopsy-proven acute rejection occurred in 15.5% of early CsA-ME and 26.5% of delayed CsA-ME patients (n.s.). Both regimens were well tolerated. These data suggest that early or delayed introduction of CsA-ME results in similar renal function in renal transplant patients regardless of DGF risk level. SN - 1600-6135 UR - https://www.unboundmedicine.com/medline/citation/16611342/Impact_of_early_or_delayed_cyclosporine_on_delayed_graft_function_in_renal_transplant_recipients:_a_randomized_multicenter_study_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=1600-6135&date=2006&volume=6&issue=5 Pt 1&spage=1042 DB - PRIME DP - Unbound Medicine ER -